Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival
暂无分享,去创建一个
M. Netea | U. Vogel | R. ter Horst | V. Moreno | D. Campa | F. Canzian | R. Reis | J. Zaucha | A. Nagler | V. Andersen | Yang Li | F. Gemignani | S. Landi | C. Dumontet | H. Avet-Loiseau | M. Kruszewski | A. Vangsted | A. Jerez | H. Marques | G. Maccari | F. Lesueur | M. Sarasquete | R. García-Sanz | D. Zawirska | A. Butrym | J. Martínez-López | K. Beider | G. Mazur | O. Ostrovsky | A. Jurczyszyn | F. Morani | J. Sainz | O. Melaiu | A. Stępień | K. Jamroziak | J. Várkonyi | M. Raźny | N. Grzasko | M. Pelosini | E. Subocz | K. Kádár | G. Szombath | Roberto Silvestri | M. S. Facioni | A. Druzd-Sitek | M. Krawczyk-Kuliś | M. Rymko | M. Wątek | A. Macauda | Diego Calvetti | Marek Dudzinski | S. E. H. Jacobsen | M. Rybicka | E. Iskierka-Jażdżewska | M. Dudzinski | K. Kadar | M. Krawczyk‐Kulis | Aleksandra Butrym
[1] B. Nilsson,et al. Genetic predisposition for multiple myeloma , 2020, Leukemia.
[2] L. Yao,et al. GOLGA7 rs11337, a Polymorphism at the MicroRNA Binding Site, Is Associated with Glioma Prognosis , 2019, Molecular therapy. Nucleic acids.
[3] Gui-Ping Xu,et al. The association between IGF1 Gene 3’-UTR polymorphisms and cancer risk , 2018, Medicine.
[4] D. Campa,et al. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients , 2018, British journal of haematology.
[5] C. Mayr. Regulation by 3'-Untranslated Regions. , 2017, Annual review of genetics.
[6] A. Allegra,et al. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma , 2017, Mediators of inflammation.
[7] H. Goldschmidt,et al. Identification of miRSNPs associated with the risk of multiple myeloma , 2017, International journal of cancer.
[8] C. Dinarello,et al. Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma , 2016, American journal of hematology.
[9] D. Lin,et al. A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer , 2016, Oncotarget.
[10] Zhenli Gao,et al. Effect of a functional polymorphism in the pre-miR-146a gene on the risk and prognosis of renal cell carcinoma. , 2015, Molecular medicine reports.
[11] Yujiang Fang,et al. The paradoxical role of IL-10 in immunity and cancer. , 2015, Cancer letters.
[12] U. Vogel,et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. , 2015, Endocrine-related cancer.
[13] W. Siffert,et al. A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1 , 2014, Molecular Cancer.
[14] D. Campa,et al. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium , 2012, Leukemia.
[15] H. Goldschmidt,et al. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium , 2012, British journal of haematology.
[16] V. Moreno,et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). , 2011, International journal of oncology.
[17] E. Platz,et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer , 2009, Cancer Causes & Control.
[18] W. Isaacs,et al. Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.
[19] Muin J. Khoury,et al. Gene Prospector: An evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases , 2008, BMC Bioinformatics.
[20] T. Therneau,et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. , 2008, Blood.
[21] A. Dispenzieri,et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[22] P. Sonneveld,et al. Multiple myeloma , 2017, Nature Reviews Disease Primers.
[23] H. Goldschmidt,et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma , 2022 .
[24] Jennifer L. Caswell-Jin,et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients , 2022 .